COMP <GO>
DERM vs ABBV // RSI-14 & 200D SMA MOMENTUM
Journey Medical Corporation (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: DERM 1
— ABBV 10
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ABBV
LAST: $5.17 (-4.44%) • MKT CAP: $152.7M
rsi-technicals
40.5
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
rsi-technicals
65.1
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DERM VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DERM | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 65.80% | 70.20% | -4.40 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -19.50% | 29.00% | -48.50 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.15% | 3.47% | -11.62 | ABBV | /fcf-yield <GO> |
| Operating Margin | -13.30% | 24.60% | -37.90 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -18.70% | 6.90% | -25.60 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 11.10% | 8.60% | +2.50 | DERM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.74 | 5.33 | -4.59 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 40.5 | 65.1 | -24.65 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $152.7M | $513.86B | -$513.71B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DERM REV | ABBV REV | DERM GROSS % | ABBV GROSS % | DERM FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $61.2M | $61.16B | 65.8% | 70.2% | -$12.4M | $17.82B |
| FY 2024 | $55.1M | $56.33B | 62.1% | 70.0% | -$9.1M | $17.83B |
| FY 2023 | $59.7M | $54.32B | — | — | $5.2M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DERM // BETA —
ABBV // BETA 1.15